Biovica Signs Agreement with American Health Giant

December 2, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / December 02, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in blood-based cancer monitoring, today announces that the company has entered into a commercial agreement (client bill) with one of the largest health insurance companies in the US, with revenues exceeding 100 billion USD. The company is both a health insurance and a health care service provider serving over 10 million...

Read more

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

November 27, 2024 8:30 AM

Interviews with participating patients from the VenoValve® U.S. Pivotal TrialWebcast replay from with the presenting Primary InvestigatorsPresentation with data from the VenoValve U.S. Pivotal TrialAccess the Recap Website Here!IRVINE, CA / ACCESSWIRE / November 27, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced the launch...

Read more

AI Maverick: The Next Evolution of Sales Automation Unveiled in Exclusive Podcast

November 27, 2024 7:30 AM

Bionoid Pharma (OTC PINK:BINP) unveils AI Maverick's game-changing sales automation in the latest episode of the BizUnLearned Podcast. Discover how this revolutionary platform is set to transform the traditional sales process, one touchpoint at a time."Imagine a world where technology doesn't just assist your sales teams but replaces repetitive tasks entirely," highlighted in the podcast. "AI Maverick learns, adapts, and delivers results,...

Read more

FluoGuide A/S Publishes Interim Report for the Period January – September 2024

November 27, 2024 1:20 AM

KØBENHAVN, DK / ACCESSWIRE / November 27, 2024 / FluoGuide A/S (STO:FLUO) Copenhagen, Denmark, 27 November 2024 - Fluoguide A/S ("FluoGuide" or the "Company") today releases its results for the period 1 January 2024 - 30 September 2024. The Q3 report is available as attached document to this press release and on FluoGuide's website.In the third quarter, preparations for the FG001 phase II head and neck trial application (CT-005) were made,...

Read more

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3

November 26, 2024 10:15 AM

Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET.The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra™, insight into the clinical status, and 2025 planned...

Read more

The End of SDRs? AI Maverick Sales Automation, One Touchpoint at a Time

November 26, 2024 7:30 AM

NEW YORK CITY, NY / ACCESSWIRE / November 26, 2024 / Bionoid Pharma, Inc. ("BINP") (OTC PINK:BINP) - Bionoid Pharma, Inc. ("Bionoid") ("BINP") (OTC Pink:BINP), the new owner of the AI Maverick platform, is disrupting the world of sales and communication industry with cutting-edge AI automation technology set to transform how businesses engage, nurture, and convert leads. While most traditional technology solutions focus on supporting overwhelmed...

Read more

New DiviTum(R) TKa data to be Presented at SABCS that Significantly Broaden the Addressable Market

November 26, 2024 2:20 AM

UPPSALA, SE / ACCESSWIRE / November 26, 2024 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B) (FRA:9II) Biovica, active in cancer monitoring, announces that seven abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest breast cancer meeting, San Antonio Breast Cancer Symposium (SABCS) on December 10-13, 2024. Two of the abstracts validates DiviTum TKa in the adjuvant setting (early breast cancer),...

Read more

Empyrean Therapeutics Acquires TLR-2 Antagonist Molecule From Eos Therapies to Advance and Commercialize Breakthrough Cancer Treatment

November 25, 2024 5:20 PM

Empyrean Therapeutics, Inc., a pioneering biopharmaceutical company, today announced the successful acquisition of a first-in-class novel TLR-2 antagonist molecule from Eos Therapies, Inc. This strategic move aims to accelerate the development of a new, safe, and effective cancer drug targeting brain, pancreatic, breast, and other hard-to-treat cancers. Designated EMS-312, it is currently in the pre-investigational new drug (pre-IND) phase and...

Read more

MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences

November 25, 2024 9:00 AM

The Institute of Biomedical Research Corp. (OTC PINK:MRES), operating as M2Bio Sciences, is a pioneering biotechnology company dedicated to advancing health and wellness through innovative science-driven solutions. Specialising in researching, developing, and commercialising cutting-edge products in nutrition, health, and sustainability. The company is also committed to groundbreaking research in mental health, gut and oral health, longevity,...

Read more

TuHURA Biosciences, Inc. (Nasdaq: HURA) Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update

November 25, 2024 8:35 AM

TuHURA Biosciences, Inc. (Nasdaq:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming targeted milestones. "We have made significant progress toward accomplishing our 2024 corporate objectives, including reaching a Special Protocol Assessment agreement with the FDA by working...

Read more

Doron Therapeutics Raises $11M Series A to Progress Biologic Regenerative Osteoarthritis Drug into Phase 3 Clinical Studies

November 25, 2024 8:00 AM

Doron Therapeutics, a clinical-stage biotech company focusing on degenerative musculoskeletal conditions, today announced it has successfully raised an aggregate $11 million as an initial Series A round to take MOTYS™ into Phase 3 clinical studies. SPRIM Global Investments (SGI), a prominent health sciences investment firm, is leading the round.Doron's most advanced product, MOTYS™, is an intra-articular biologic drug developed for the...

Read more

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment

November 22, 2024 9:15 AM

Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, discusses positive preclinical data recently presented at the Society for Immunotherapy of Cancer (SITC) 39th Annual MeetingWatch the "What This Means" video hereFRAMINGHAM, MA / ACCESSWIRE / November 22, 2024 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative...

Read more

Therabene Inc. Press Release

November 21, 2024 2:10 PM

Therabene Inc., an emerging biotech company at the forefront of developing advanced cancer therapies, is pleased to announce positive preclinical results for two new novel molecules targeting aggressive cancers. Conducted in collaboration with local biotech service provider Biocytogen, the study results highlight the efficacy of Therabene's innovative approach to cancer treatment, with both new molecules demonstrating compelling tumor reduction...

Read more

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis

November 21, 2024 8:30 AM

Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced the presentation of preclinical data investigating the potential of co-administration of deoxyribonuclease I (DNase I) with chimeric antigen receptor (CAR) T cells in a syngeneic B16 melanoma murine model of lung metastasis.The poster...

Read more

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies

November 20, 2024 6:25 PM

Biomind Labs Inc. (" Biomind " or the " Company ") (CBOE:BMND)(OTC PINK:BMNDF)(FRA:3XI) , a leading biotech company at the forefront of next-generation pharmaceuticals addressing the root causes of neurological disorders, is encouraged by the U.S. government's progressive stance on the psychedelic industry. The administration's decision to nominate a new Health Secretary with a history of supporting innovative mental health solutions marks a...

Read more

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

November 20, 2024 8:30 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, will present one year data on all subjects from the VenoValve U.S. pivotal trial today at the 51st Annual Vascular and Endovascular, Techniques and Horizons (VEITH) Symposium in New York City. The definitive one-year data supports the application submitted earlier this week by enVVeno Medical...

Read more

A New Stem Cell Therapy for Parkinson's Disease Has Been Confirmed Safe and Effective for the First Time

November 19, 2024 3:25 PM

Nature Cell Co., Ltd., a leading biotech company based in Korea, announced on November 19th that it has confirmed the success of a new treatment involving the intravenous and spinal cavity administration of autologous adipose stem cells. This treatment was developed in collaboration with Japan Angel Stem Cell (JASC) and R Bio, which utilized stem cell culture media produced and supplied by Nature Cell. The new treatment has shown promising...

Read more

Biotech Industry Leader Andrew Young from Wellesley Launches New Personal Website

November 19, 2024 12:00 PM

Andrew Young, the esteemed CEO and Managing Partner of Conjugate Group, a renowned biotechnology staffing and business development firm, has officially launched his personal website. This new platform will serve as a hub for sharing his extensive professional experiences and offering valuable advice to the next generation of industry professionals.Andrew Young's career spans over two decades in the staffing industry, particularly in the biotech...

Read more

Alligator Announces Sale of Future Financial Commitments for Two Bispecific Antibodies to Orion Corporation

November 19, 2024 11:45 AM

Transaction valued at €3.5 millionThe partners have enjoyed a successful discovery collaboration since 2021LUND, SWEDEN / ACCESSWIRE / November 19, 2024 / Alligator Bioscience (STO:ATORX) today announced that the Company has entered into an agreement under which Orion Corporation has settled all future contractual milestones, royalty and any other commitments towards Alligator in relation to two preclinical bispecific antibodies resulting from...

Read more

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

November 19, 2024 8:15 AM

enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, today announced it has submitted its application with the U.S. Food and Drug Administration (FDA) seeking approval to market and sell the VenoValve in the United States. Four (4) out of five (5) modules that comprise the VenoValve PMA application have been submitted, reviewed and approved by the...

Read more